Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | US

Overview

Corporate Details

ISIN(s):
US3968791083
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation ISKJ
HUMASIS CO., LTD. Logo
Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.
South Korea 205470
Humedix Co., Ltd. Logo
Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.
South Korea 200670
HUONS CO., LTD. Logo
Global healthcare company providing pharmaceuticals, medical devices, and wellness products.
South Korea 243070
Huons Global Co., Ltd. Logo
Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.
South Korea 084110
Hong Kong HCM
HUTCHMED (China) Ltd Logo
Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.
United States of America HCM
HWAIL PHARM. CO., LTD Logo
Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.
South Korea 061250
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
HYUNDAI BIOLAND Co.,Ltd. Logo
Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.
South Korea 052260

Talk to a Data Expert

Have a question? We'll get back to you promptly.